Lakehead University Library Logo
    • Login
    View Item 
    •   Knowledge Commons
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations from 2009
    • View Item
    •   Knowledge Commons
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations from 2009
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    quick search

    Browse

    All of Knowledge CommonsCommunities & CollectionsBy Issue DateAuthorTitleSubjectDisciplineAdvisorCommittee MemberThis CollectionBy Issue DateAuthorTitleSubjectDisciplineAdvisorCommittee Member

    My Account

    Login

    Statistics

    View Usage Statistics

    Adipose tissue remodeling in response to corticosterone and β3-adrenergic receptor agonist mirabegron

    Thumbnail

    View/Open

    BelJ2022m-1a.pdf (14.20Mb)

    Date

    2022

    Author

    Bel, Jocelyn Susan

    Degree

    Doctor of Philosophy

    Discipline

    Biotechnology

    Subject

    Adipose tissue
    Corticosterone
    Metabolic dysfunction
    Mirabegron treatments

    Metadata

    Show full item record

    Abstract

    With the rise of metabolic diseases including obesity and type 2 diabetes, the need to investigate one of the most dynamic endocrine organs is critical for combating these diseases. Adipose tissue (AT) exists predominantly in two forms: white AT (WAT) and brown AT (BAT). This study set out to investigate how chronic levels of glucocorticoids (GC), namely corticosterone, influence AT, and if the negative effects of GCs can be combated with a β3-adrenergic receptor (β3AR) agonist, mirabegron. Mice were subjected to oral treatments of either, corticosterone (500µg/day), mirabegron (either 0.024mg/day or 0.24mg/day), a combination of the two, or naïve or vehicle (<1% ethanol) controls for four weeks. The corticosterone dose was chosen to match the level of corticosterone circulating in Cushing’s syndrome patients, and the mirabegron treatments were chosen to be a much lower dose (0.024mg/day) than or to closely resemble the maximal dosage approved (0.24mg/day) for overactive bladder patients. We hypothesized that mirabegron would offset the negative impacts of corticosterone-induced metabolic dysfunction and lipid accumulation within the AT depots. Corticosterone treatment resulted in BAT whitening, significantly (p≤0.05) increased body and AT weights, whole-body insulin resistance and circulating leptin levels. [...]

    URI

    https://knowledgecommons.lakeheadu.ca/handle/2453/4961

    Collections

    • Electronic Theses and Dissertations from 2009

    Lakehead University Library
    Contact Us | Send Feedback

     


    Lakehead University Library
    Contact Us | Send Feedback